跳至主要内容
临床试验/CTRI/2024/06/068272
CTRI/2024/06/068272尚未招募2 期

Comparison of Responses after two Total Neoadjuvant Treatment Protocols in Rectal Cancer: A prospective phase II Randomised Controlled Trial - RETAI

A0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方
A

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Older than 18 years of age and less than 70 years
  • 2.Clinical stage II (T3c-T4, N0) or stage III (any T, N1-2) biopsy proven rectal adenocarcinoma staged with magnetic resonance imaging (MRI), a full colonoscopy, and computed tomography (CT) of the chest, abdomen, and pelvis.
  • 3.Eastern Cooperative Oncology Group (ECOG) score 0-1
  • 4.Fit for Capecitabine-Oxaliplatin(CAP-OX) or FOLFOX based chemotherapy
  • 5. Tumors located up to 10 cm from anal verge
  • 6. Blood parameters: a white blood cell count of 4·0 × 10 ? cells per L or higher, platelet count of 100 × 10 ? per L or higher, a clinically acceptable haemoglobin level, a creatinine level indicating renal clearance of 50 mL/min or higher, and bilirubin level below 2mg/dl.

排除标准

  • 1.Evidence of distant metastasis
  • 2. Recurrent disease
  • 3. Prior history of pelvic irradiation
  • 4.Pelvic Kidney
  • 5. Collagen vascular disease
  • 6.ECOG performance status 2-3
  • 7. Deranged kidney function tests
  • 8.Not fit for Cap-OX or FOLFOX based chemotherapy

研究者

发起方
A

相似试验